Registrational Phase III CLARIFY trial: Target number of participants achieved

Clarity Pharmaceuticals said its registrational Phase III CLARIFY trial has dosed its planned target of 383 participants, completing recruitment. Topline results assessing sensitivity and specificity of 64Cu-SAR-bisPSMA for prostate-cancer imaging are expected in the first half of 2027; the company says the results are intended to support a potential US FDA application. Earlier Phase I data reported approximately 30% greater lesion detection versus 68Ga-PSMA-11, but the product remains unregistered and its safety and efficacy have not been assessed by health authorities.

Analysis

The recruitment milestone removes enrollment risk, not clinical or regulatory risk. The value inflection is the 1H27 readout: sensitivity matters, but specificity and whether imaging changes treatment decisions will determine whether a diagnostic advantage translates into adoption and reimbursement. CLARIFY’s surgically verified endpoint is useful for accuracy assessment, yet its high-risk, pre-prostatectomy cohort may not establish utility across broader prostate-cancer populations. The company’s comparison with existing agents is not a head-to-head registrational efficacy result; the small Phase I evidence should not be treated as proof of superiority.

If results are compelling, established PSMA PET providers face a potential share and pricing challenge in initial staging, while imaging centers could benefit from greater scan demand. That upside is conditional: centralized supply and next-day imaging flexibility must work operationally, and an extra-day workflow could constrain scheduling versus same-day alternatives. Copper-67 therapy is longer-dated platform optionality, not a reason to value the current diagnostic program as a therapeutic franchise.

Near term, recruitment completion may support sentiment, but without data it does not resolve the binary efficacy question. Over 1–3 months, monitor trial follow-up and any disclosure on readout timing; the main catalyst is expected in 1H27 alongside AMPLIFY. A weak sensitivity result, inadequate specificity, or delayed readout could unwind milestone-driven optimism. Longer term, FDA review, reimbursement, manufacturing reliability, and clinician adoption remain unproven. No valuation, liquidity, or position data are supplied, so there is no well-grounded directional trade today.

Key Decisions for Investors

• Do not chase the recruitment headline as a read-through to efficacy; treat Clarity Pharmaceuticals as a 1H27 clinical readout event, not a de-risked commercial story.
• Keep the company on a catalyst watchlist and verify readout timing, cash runway, current valuation, trial endpoint thresholds, and whether results will include clinically meaningful specificity and management-impact data before sizing exposure.
• If holding, define event-risk limits ahead of CLARIFY and AMPLIFY topline results. Falsifiers include missed prespecified accuracy thresholds, specificity that undermines clinical utility, or a material readout delay.
• On positive data, assess commercial feasibility separately: evidence of incremental treatment decisions, reimbursement, centralized manufacturing capacity, and practical next-day scan workflows are needed before extrapolating share gains from incumbent PSMA PET agents.